Marcus A. Carden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marcus A. Carden has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Clinton H. Joiner
Division of Pediatric Hematology/Oncology, Department of Pediatrics, Aflac Cancer & Blood Disorders Center, Emory University School of Medicine, Atlanta, GA
3 shared publications- Wilbur A. Lam
The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA, USA
3 shared publications Yumiko Sakurai
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 345 Ferst Drive, Atlanta, GA, 30332, USA
3 shared publicationsMeredith E. Fay
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 345 Ferst Drive, Atlanta, GA, 30332, USA
2 shared publicationsRobert G. Mannino
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 345 Ferst Drive, Atlanta, GA, 30332, USA
2 shared publications- Ross M. Fasano
Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine Emory University School of Medicine Atlanta Georgia USA
2 shared publications
Latest Publications
- 23 October 2024
- Published by Wiley in American Journal of Hematology
- Vol. 100 (1) , 144-148
Emergency department intravenous fluid resuscitation and renal outcomes among adults with sickle cell disease
- 23 October 2024
- Published by Wiley in American Journal of Hematology
- Vol. 100 (1) , 144-148
Emergency department intravenous fluid resuscitation and renal outcomes among adults with sickle cell disease
- 3 May 2022
- Published by Wiley in British Journal of Haematology
- Vol. 198 (2) , 397-400
Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study
- 3 May 2022
- Published by Wiley in British Journal of Haematology
- Vol. 198 (2) , 397-400
Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study
- 27 January 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (4) , e29566
Building the foundation of health‐related knowledge via near‐peer education for children with sickle cell disease
Health education for children with chronic illnesses (i.e., sickle cell disease [SCD]) has focused on educating adult caregivers with minimal consideration to educating the pediatric patients. We introduce a pediatric‐focused educational paradigm, health‐related knowledge (HRK), teaching pediatric patients developmentally appropriate general health literacy, and disease‐specific knowledge. Using science, technology, engineering, and mathematics (STEM) education concepts, pediatric‐specific HRK interactive activities address educational gaps: (a) general STEM education; and (b) general health and disease‐specific knowledge to improve clinical outcomes. Total 144 pediatric SCD patients completed HRK activities, revealing overwhelmingly positive feedback (87%). Seventy‐five percent of participants in 6th grade and above demonstrated thorough understanding of the STEM/HRK topics taught.
- 27 January 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (4) , e29566
Building the foundation of health‐related knowledge via near‐peer education for children with sickle cell disease
Health education for children with chronic illnesses (i.e., sickle cell disease [SCD]) has focused on educating adult caregivers with minimal consideration to educating the pediatric patients. We introduce a pediatric‐focused educational paradigm, health‐related knowledge (HRK), teaching pediatric patients developmentally appropriate general health literacy, and disease‐specific knowledge. Using science, technology, engineering, and mathematics (STEM) education concepts, pediatric‐specific HRK interactive activities address educational gaps: (a) general STEM education; and (b) general health and disease‐specific knowledge to improve clinical outcomes. Total 144 pediatric SCD patients completed HRK activities, revealing overwhelmingly positive feedback (87%). Seventy‐five percent of participants in 6th grade and above demonstrated thorough understanding of the STEM/HRK topics taught.
- 3 July 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (9) , e28499
Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy
In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c) is unreliable and the American Diabetes Association recommends monitoring long‐term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, has been reported. SF as a screen for DM in SCD, however, is not standardized and its relationship to serum glucose has not been validated. Further, screening for DM was not adequately addressed in the 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines for SCD management. Blood transfusions, an important treatment for some patients with SCD, can also impact HbA1c. We present a case of a patient with SCD and cystic fibrosis‐related diabetes on monthly chronic transfusions therapy (CTT) who had well‐correlated “steady state” HbA1c and SF levels over time, suggesting for the first time these markers may actually be useful when following long‐term glycemic control in patients with SCD on CTT programs.
- 3 July 2020
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (9) , e28499
Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy
In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c) is unreliable and the American Diabetes Association recommends monitoring long‐term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, has been reported. SF as a screen for DM in SCD, however, is not standardized and its relationship to serum glucose has not been validated. Further, screening for DM was not adequately addressed in the 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines for SCD management. Blood transfusions, an important treatment for some patients with SCD, can also impact HbA1c. We present a case of a patient with SCD and cystic fibrosis‐related diabetes on monthly chronic transfusions therapy (CTT) who had well‐correlated “steady state” HbA1c and SF levels over time, suggesting for the first time these markers may actually be useful when following long‐term glycemic control in patients with SCD on CTT programs.
- 1 March 2020
- Published by Elsevier in Blood Reviews
- Vol. 40, 100637
Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia
- 1 March 2020
- Published by Elsevier in Blood Reviews
- Vol. 40, 100637
Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia
- Open Access
- 27 March 2019
- Published by Wiley in American Journal of Hematology
- Vol. 94 (6) , 689-696
Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso‐occlusive pain
Vaso‐occlusive pain events (VOE) are the leading cause of emergency department (ED) visits in sickle cell anemia (SCA). This study assessed the variability in use of intravenous fluids (IVFs), and the association of normal saline bolus (NSB), on pain and other clinical outcomes in children with SCA, presenting to pediatric emergency departments (PED) with VOE. Four‐hundred charts of children age 3‐21 years with SCA/VOE receiving parenteral opioids at 20 high‐volume PEDs were evaluated in a retrospective study. Data on type and amount of IVFs used were collected. Patients were divided into two groups: those who received NSB and those who did not. The association of NSB use on change in pain scores and admission rates was evaluated. Among 400 children studied, 261 (65%) received a NSB. Mean age was 13.8 ± 4.9 years; 46% were male; 92% had hemoglobin‐SS. The IVFs (bolus and/or maintenance) were used in 84% of patients. Eight different types of IVFs were utilized and IVF volume administered varied widely. Mean triage pain scores were similar between groups, but improvement in pain scores from presentation‐to‐ED‐disposition was smaller in the NSB group (2.2 vs 3.0, P = .03), while admission rates were higher (71% vs 59%, P = .01). Use of NSB remained associated with poorer final pain scores and worse change in pain scores in our multivariable model. In conclusion, wide variations in practice utilizing IVFs are common. NSB is given to >50% of children with SCA/VOE, but is associated with poorer pain control; a controlled prospective trial is needed to determine causality.
- 27 March 2019
- Published by Wiley in American Journal of Hematology
- Vol. 94 (6) , 689-696
Open AccessNormal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso‐occlusive pain
Vaso‐occlusive pain events (VOE) are the leading cause of emergency department (ED) visits in sickle cell anemia (SCA). This study assessed the variability in use of intravenous fluids (IVFs), and the association of normal saline bolus (NSB), on pain and other clinical outcomes in children with SCA, presenting to pediatric emergency departments (PED) with VOE. Four‐hundred charts of children age 3‐21 years with SCA/VOE receiving parenteral opioids at 20 high‐volume PEDs were evaluated in a retrospective study. Data on type and amount of IVFs used were collected. Patients were divided into two groups: those who received NSB and those who did not. The association of NSB use on change in pain scores and admission rates was evaluated. Among 400 children studied, 261 (65%) received a NSB. Mean age was 13.8 ± 4.9 years; 46% were male; 92% had hemoglobin‐SS. The IVFs (bolus and/or maintenance) were used in 84% of patients. Eight different types of IVFs were utilized and IVF volume administered varied widely. Mean triage pain scores were similar between groups, but improvement in pain scores from presentation‐to‐ED‐disposition was smaller in the NSB group (2.2 vs 3.0, P = .03), while admission rates were higher (71% vs 59%, P = .01). Use of NSB remained associated with poorer final pain scores and worse change in pain scores in our multivariable model. In conclusion, wide variations in practice utilizing IVFs are common. NSB is given to >50% of children with SCA/VOE, but is associated with poorer pain control; a controlled prospective trial is needed to determine causality.
- 8 March 2019
- Published by Wiley in Transfusion
- Vol. 59 (5) , 1698-1705
Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients
BACKGROUND: Delayed hemolytic transfusion reactions (DHTRs) are serious complications of RBC transfusion that can occur in previously alloimmunized patients. Patients who require episodic transfusions during heightened inflammatory states, such as patients with sickle cell disease (SCD), are particularly prone to alloimmunization and developing DHTRs with hyperhemolysis. While efforts to mitigate these hemolytic episodes via immunosuppressive drugs can be employed, the relative efficacy of various treatment options remains incompletely understood.CASE REPORTS: In this study, we explored five patients with SCD and multiple RBC alloantibodies who received various forms of immunosuppressive therapy in an attempt to prevent or treat severe DHTRs.RESULTS: The clinical course for these five patients provides insight into the difficulty of effectively treating and preventing DHTRs in patients with SCD with currently available immunosuppressive therapies.CONCLUSION: Based on our experience, and the current literature, it is difficult to predict the potential impact of various immunosuppressive therapies when seeking to prevent or treat DHTRs. Future mechanistic studies are needed to identify the optimal treatment options for DHTRs in the presence or absence of distinct alloantibodies in patients with SCD.
- 8 March 2019
- Published by Wiley in Transfusion
- Vol. 59 (5) , 1698-1705
Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients
BACKGROUND: Delayed hemolytic transfusion reactions (DHTRs) are serious complications of RBC transfusion that can occur in previously alloimmunized patients. Patients who require episodic transfusions during heightened inflammatory states, such as patients with sickle cell disease (SCD), are particularly prone to alloimmunization and developing DHTRs with hyperhemolysis. While efforts to mitigate these hemolytic episodes via immunosuppressive drugs can be employed, the relative efficacy of various treatment options remains incompletely understood.CASE REPORTS: In this study, we explored five patients with SCD and multiple RBC alloantibodies who received various forms of immunosuppressive therapy in an attempt to prevent or treat severe DHTRs.RESULTS: The clinical course for these five patients provides insight into the difficulty of effectively treating and preventing DHTRs in patients with SCD with currently available immunosuppressive therapies.CONCLUSION: Based on our experience, and the current literature, it is difficult to predict the potential impact of various immunosuppressive therapies when seeking to prevent or treat DHTRs. Future mechanistic studies are needed to identify the optimal treatment options for DHTRs in the presence or absence of distinct alloantibodies in patients with SCD.
- 1 February 2019
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (1) , 1-6
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma
- 1 February 2019
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (1) , 1-6
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma
- 1 June 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (9) , e27267
Autologous stem‐cell transplant for metastatic renal medullary carcinoma
- 1 June 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (9) , e27267
Autologous stem‐cell transplant for metastatic renal medullary carcinoma